Graft vs Host Disease: all 815 studies

Page 6 of 9. Open to participants first (138), then studies with results posted, then the rest; newest registration first within each.

• Topical Vitamin D in Acute Graft Versus Host Disease of the SkinCompletedNCT03093805Not applicable
• Extracorporeal Photopheresis Using Theraflex ECP™ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD)Status unknownNCT03083574Phase 2
• Blood Based Eyedrops From Different Sources in the Treatment of Severe KeratopathyStatus unknownNCT03064984Not applicable
• Ruxolitinib for Steroid-refractory GVHDCompletedNCT02997280Phase 2
• A Prospective Observational Study for Evaluating CGVHDCompletedNCT02991846
• The Influence of TaKeTiNa Music Therapy, Traditional Chinese Acupuncture and Clown Theatrical Performance on Quality of Life and the Therapeutic Process of Patients Undergoing Allogenic Stem Cell TransplantationTerminatedNCT02976558Not applicable
• CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCTCompletedNCT02942173Phase 2/3
• A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host DiseaseCompletedNCT02923375Phase 1
• MicroRNAs as Diagnostic and Predictive Biomarkers for Acute Graft Versus Host DiseaseWithdrawnNCT02917148
• Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the HostCompletedNCT02891395Phase 2
• Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCTCompletedNCT02876679Phase 2
• Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell DiseaseCompletedNCT02867800Phase 1
• T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation.TerminatedNCT02849886Phase 1/2
• Ectoin Dermatitis Cream 7% as First-line Therapy of Acute Skin Graft Versus Host DiseaseWithdrawnNCT02842372
• Graft-versus-host Disease Associated MyelosuppressionStatus unknownNCT02829216
• Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell TransplantationStatus unknownNCT02828878Phase 1/2
• Allogenic Bone Marrow Mesenchymal Stem Cells Infusion in Patients With Steroid-refractory GVHDCompletedNCT02824653Phase 1/2
• Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCTCompletedNCT02812940Phase 2
• Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal InfectionsCompletedNCT02805946Phase 4
• Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related TransplantationStatus unknownNCT02799888Phase 2
• Mesenchymal Stem Cells as First Treatment Line for Resistant Acute Graft Versus Host DiseaseStatus unknownNCT02770430Phase 2
• Evaluation of a Kit for the Prediction of the Risk of Graft Versus Host DiseaseTerminatedNCT02751112Not applicable
• Multiple Donor Treg DLI for Severe Refractory Chronic GVHDCompletedNCT02749084Phase 1/2
• Ocular Surface Disease in Chronic Graft-Versus-Host Disease (GVHD) PatientsCompletedNCT02712762
• Early Detection of Mucosal Abnormalities in Graft-versus-host DiseaseCompletedNCT02707354Not applicable
• Clinical Trial With MSC for Graft Versus Host Disease TreatmentCompletedNCT02687646Phase 1/2
• Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling DonorCompletedNCT02660684Phase 4
• Prophylaxis Roles of IL-2 Treatment on GVHD After TransplantationStatus unknownNCT02659657Phase 2
• Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHDCompletedNCT02614612Phase 1
• Safety and Efficacy of Autologous PRP and PPP Eye Drops in the Treatment of Ocular GVHDWithdrawnNCT02561520Phase 1
• Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With MyelofibrosisWithdrawnNCT02528877Phase 1
• Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell TransplantWithdrawnNCT02526329Phase 1
• The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation OutcomeStatus unknownNCT02506231Phase 2/3
• Irradiated Blood Versus Non Irradiated Blood Transfusions in Craniosynostosis RepairCompletedNCT02483702Not applicable
• Extended Use of Cannabidiol for the Prevention of Graft-versus-host-diseaseStatus unknownNCT02478424Phase 2
• A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell TransplantTerminatedNCT02436460Phase 1
• Methylprednisolone Sodium Succinate in Treating Patients With Acute Graft-versus-Host Disease of the Gastrointestinal TractWithdrawnNCT02425813Phase 2
• Fucosylated T Cells for Graft Versus Host Disease (GVHD) PreventionCompletedNCT02423915Phase 1
• Tear Cytokine Analysis as a Prediction or Diagnostic Marker in Ocular GvHDCompletedNCT02411474
• Cognitive Function and Patient-Reported Quality of Life Outcomes Investigation in Patients Taking VorinostatCompletedNCT02409134
• Comparison of Gut Microbiota, Inflammation and Symptoms Following Allogeneic HSCTCompletedNCT02398708
• Ruxolitinib In GvHDTerminatedNCT02396628Phase 2
• Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host DiseaseStatus unknownNCT02392780Phase 2
• CINC424A2X01B Rollover ProtocolActive, not recruitingNCT02386800Phase 4
• A Phase 1/2 Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-DiseaseStatus unknownNCT02385019Phase 1/2
• BMT Autologous MSCs for GvHDCompletedNCT02359929Phase 1
• Evaluation of the Diagnostic Value of PET (18F-FDG) in Chronic Graft Versus Host Disease (cGVH)Status unknownNCT02352064Not applicable
• Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell TransplantationCompletedNCT02342613Phase 1
• Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia MajorCompletedNCT02342145Phase 4
• Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell TransplantationCompletedNCT02337595Phase 1/2
• Toward Immune Biomarkers for Tolerance and GvHD in HumansStatus unknownNCT02319226
• Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell TransplantStatus unknownNCT02300571
• Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal CellsStatus unknownNCT02291770Phase 3
• Biomarkers for Acute Graft-versus-host DiseaseStatus unknownNCT02254798
• MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHDStatus unknownNCT02241018Phase 2/3
• Tacrolimus and Mycophenolate Mofetil as Post-Grafting ImmunosuppressionStatus unknownNCT02178683Phase 3
• Pharmacological Predictors of Successful Cyclosporine Acute GVHD Prophylaxis in Children Undergoing HSCTCompletedNCT02175615
• Tocilizumab for Chronic Graft-versus-Host Disease TreatmentWithdrawnNCT02174263Phase 2
• Decidual Stromal Cells as Treatment for Acute Graft Versus Host Disease, a Phase 1-2 StudyStatus unknownNCT02172937Phase 1/2
• A Phase 2 Study Using Placenta Derived Decidual Stromal Cells for Graft Versus Host DiseaseStatus unknownNCT02172924Phase 1/2
• Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal DiseaseCompletedNCT02172768Phase 2
• Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)TerminatedNCT02151539
• Prevention of Ocular Graft-Versus-Host Disease With Topical Cyclosporine in Recipients of Allogeneic HSCTCompletedNCT02144025Phase 2
• Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT02117115Early Phase 1
• Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCTTerminatedNCT02086513Phase 1
• Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host DiseaseActive, not recruitingNCT02067832
• CEC Count Changes to Support GvHD Diagnosis.CompletedNCT02064972
• Mesenchymal Stem Cells as a Treatment for Oral Complications of Graft-versus-host DiseaseWithdrawnNCT02055625Phase 1/2
• Clinical Implications of HMGB1 in Patients Treated With Chemotherapy or Hematopoietic Stem Cell TransplantationStatus unknownNCT02044185
• Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host DiseaseStatus unknownNCT02032446Phase 1/2
• Safety and Efficacy Study of T-Guard to Treat Steroid-resistant Acute GVHDCompletedNCT02027805Phase 1/2
• CliniMACS® CD34+ Reagent System for Expanded Access UseNo longer availableNCT02026934
• Preemptive Therapy of GVHDTerminatedNCT01994824Phase 2
• Carfilzomib for the Prevention of Graft Versus Host DiseaseStatus unknownNCT01991301Phase 1
• Lymphocyte Profiles and Activation Status in Patients With Graft-Versus-Host DiseaseWithdrawnNCT01988701
• Positron Emission Tomography - Computed Tomography (PET-CT) Scanning in Chronic Graft Versus Host Disease (cGvHD)TerminatedNCT01964625Not applicable
• Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell.CompletedNCT01956903Phase 1/2
• Evaluation of Budesonide and How It Interacts With Antifungal Drugs in People With Gastrointestinal Graft-Versus-Host DiseaseTerminatedNCT01950507Phase 1
• Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis TransplantationStatus unknownNCT01941394Phase 2
• Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)TerminatedNCT01940796Phase 1
• A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant PatientsCompletedNCT01926899Phase 1
• Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHDCompletedNCT01911039Phase 1
• Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)TerminatedNCT01903473Phase 2
• Chronic GVHD Response Measures ValidationActive, not recruitingNCT01902576
• Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in ChildrenTerminatedNCT01898377Phase 2
• ATG in Haploidentical HSCT for Acute Graft-versus-host Disease ProphylaxisCompletedNCT01883180Phase 4
• Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell TransplantationWithdrawnNCT01882387Phase 2
• Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood TransplantationWithdrawnNCT01882374Phase 2
• Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and EverolimusCompletedNCT01862965Phase 2
• G-CSF Moblized Peripheral Harvest for Poor Engraftment After Stem Cell TransplantationCompletedNCT01857336Not applicable
• Collection of Saliva and/ or Peripheral Blood From Healthy Volunteers for ResearchCompletedNCT01851382
• T&B Depletion Non MalignantStatus unknownNCT01810926Phase 2
• Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHDCompletedNCT01810718Phase 1
• Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host DiseaseCompletedNCT01795573Phase 1
• Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host DiseaseCompletedNCT01788501Phase 2/3
• Mesenchymal Stem Cells for Treatment of Refractory Chronic Graft-versus-host DiseaseStatus unknownNCT01765660Phase 2
• Mesenchymal Stem Cells for Treatment of Refractory Acute Graft-versus-host DiseaseStatus unknownNCT01765634Phase 2
• Mesenchymal Stromal Cells (MSCs) for the Treatment of Graft Versus Host Disease (GVHD)Status unknownNCT01764100Phase 1
• Microvascular and Fibrosis Imaging StudyCompletedNCT01758250
• Safety and Efficacy of UC-MSC in Patients With Acute Severe Graft-versus-host DiseaseStatus unknownNCT01754454Phase 1/2

← Graft vs Host Disease overview